What are Qilu Pharmaceutical Co., Ltd.'s marketed drugs?

Top marketed products include Ceftazidime-avibactam, DARZALEX FASPRO®, Prolia®, QL0605(PEG-rhG-CSF), Tafamidis Meglumine Soft Capsules, Tezspire.

Qilu Pharmaceutical Co., Ltd.

7 marketed · 41 in Phase 3

Quick facts

Marketed products

Ceftazidime-avibactam · Infectious Disease
Ceftazidime-avibactam is a combination of a third-generation cephalosporin antibiotic and a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
DARZALEX FASPRO®
Prolia®
QL0605(PEG-rhG-CSF) · Oncology
QL0605 is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells to increase white blood cell production.
Tafamidis Meglumine Soft Capsules · Rare disease / Neurology / Cardiology
Tafamidis stabilizes transthyretin (TTR) protein tetramers, preventing their dissociation and misfolding into amyloid fibrils.
Tezspire · Respiratory
Xiidra · Other

Phase 3 pipeline

CAPEOX/Capecitabine · Oncology
Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival.
ESG401
ESG401 is an investigational drug in phase 3 development by Qilu Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
GM1 · Neurology
GM1 is a monosialotetrahexosylganglioside that promotes neuronal protection and regeneration by enhancing nerve growth factor signaling and reducing neuroinflammation.
Meropenem and Pralurbactam · Infectious Disease
Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria.
MHB088C for Injection · Oncology
MHB088C is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
Monosialoganglioside · Other
Olanzapine-samidorphan； · Psychiatry
Olanzapine-samidorphan is an atypical antipsychotic that combines the antipsychotic effects of olanzapine with the weight loss effects of samidorphan.
pALG/ rATG · Immunology
pALG and rATG are immunosuppressive drugs that work by inhibiting T-cell activation and proliferation.
placebo for QL1604
This drug is a placebo, meaning it has no active therapeutic effect.
Placebo for QLS31905
This is a placebo control with no active pharmacological mechanism.
QL0911 · Diabetes
QL0911 is a small molecule drug that targets the SGLT2 receptor.
QL1012 · unknown
QL1012 is a small molecule that targets the molecular target.
QL1101 · Oncology
QL1101 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
QL1203 · Diabetes
QL1203 is a small molecule that targets the SGLT2 receptor.
QL1206 · Diabetes
QL1206 is a small molecule drug that targets the SGLT2 receptor.
QL1207H injection
QL1207H injection's mechanism is not publicly available.
QL1209 · Diabetes
QL1209 is a small molecule that targets the SGLT2 receptor.
QL1604 · Diabetes
QL1604 is a small molecule drug that targets the SGLT2 receptor.
QL1701 · Endocrinology / Diabetes
QL1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
QL2107 · Diabetes
QL2107 is a small molecule drug that targets the SGLT2 receptor.
QL2108 injection
QL2108 injection's mechanism is not publicly available.
QL2109 · Diabetes
QL2109 is a small molecule drug that targets the SGLT2 receptor.
QLC5508 · unknown
QLC5508 is a small molecule drug that targets the molecular target.
QLC7401
QLC7401 is a small-molecule inhibitor that targets specific cellular pathways involved in disease progression.
QLG1080 · Diabetes
QLG1080 is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
QLG1091 · unknown
QLG1091 is a small molecule drug that targets the molecular target.
QLG2128
QLG2128 is a small molecule inhibitor targeting a specific molecular pathway relevant to its therapeutic indication.
QLM2010 for injection；dexamethasone · Oncology
Dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation.
QLM3003 · Cardiovascular
QLM3003 is a small molecule drug that targets the molecular target.
QLM3004 Concentration 1
QLM3004 Concentration 1 is a drug that targets the molecular target to exert its therapeutic effect.
QLM3004 Concentration 2
QLM3004 Concentration 2 is a drug that targets the molecular target to exert its therapeutic effect.
QLM3004 Concentration 3 · unknown
QLM3004 Concentration 3 is a drug that works by inhibiting the activity of a specific molecular target.
QLS1128
QLS1128 is a small molecule inhibitor targeting a specific molecular pathway in phase 3 development by Qilu Pharmaceutical.
QLS31905 · Diabetes
QLS31905 is a small molecule drug that targets the SGLT2 receptor.
QLS32015 · Diabetes
QLS32015 is a small molecule drug that targets the SGLT2 receptor.
Romiplostim N01 · Hematology
Romiplostim N01 is a thrombopoietin receptor agonist that stimulates platelet production.
tezepelumab (Arm1&Arm2) · Immunology
Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation.
Tilesizumab · Other
VB4-845 Injection · Oncology
VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation.
Voclosporin（QL1074） · Immunology
Voclosporin is an immunosuppressant that inhibits calcineurin.

Phase 2 pipeline

CEND-1
Dose 1 of QLS1410 · Diabetes
QLS1410 is a small molecule that targets the SGLT2 receptor.
gefitinib combined with apatinib
gefitinib combined with chemotherapy
gefitinib single agent
Meropenem- FL058
QL-007 tablet
QL1706 Plus Lenvatinib
QL2109 or Daratumumab
QLF31907
QLS12010
WX-0593

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: